Skip to main content

Table 2 Symptom-burden within 14 days after the first vaccination (short-term survey)

From: Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study

 

Short-term survey after first vaccination

N

mRNA

Vector

Comparator

BNT

MOD

AZ

JAN

2044

687

177

155

203

At least one symptom (N (%))

 

1437 (70.3)

570 (83.0)

151 (85.3)

125 (80.6)

108 (53.2)

At least one local reaction (N (%))

 

1175 (57.5)

508 (73.9)

96 (54.2)

74 (47.7)

87 (42.9)

 Consequences of local reactions (%)

  No consequences

95.0

86.2

94.8

90.5

97.7

  Medication intake

3.0

8.5

4.2

6.8

2.3

  Sick leave

1.0

3.0

1.0

1.4

0.0

  Ambulatory consultation

1.0

2.0

0.0

1.4

0.0

  Hospital outpatient consultation

0.0

0.4

0.0

0.0

0.0

  Hospitalisation

0.0

0.0

0.0

0.0

0.0

At least one systemic reaction (N (%))

 

992 (48.5)

407 (59.2)

145 (81.9)

120 (77.4)

66 (32.5)

 Consequences of systemic reactions (%)

  No consequences

71.3

67.1

46.2

40.8

81.8

  Medication intake

19.5

21.6

37.9

33.3

13.6

  Sick leave

4.5

5.4

11.0

23.3

3.0

  Ambulatory consultation

3.8

5.9

4.8

2.5

1.5

  Hospital outpatient consultation

0.6

0.0

0.0

0.0

0.0

  Hospitalisation

0.3

0.0

0.0

0.0

0.0

At least one unsolicited reaction (N (%))

 

198 (9.7)

95 (13.8)

28 (15.8)

17 (11.0)

11 (5.4)

 Consequences of unsolicited reactions (%)

  No consequences

67.2

72.6

75.0

52.9

45.5

  Medication intake

14.6

10.5

10.7

23.5

9.1

  Sick leave

6.1

2.1

3.6

23.5

27.3

  Ambulatory consultation

11.1

14.7

7.1

0.0

2.0

  Hospital outpatient consultation

0.5

0.0

3.6

0.0

0.0

  Hospitalisation

0.5

0.0

0.0

0.0

0.0

  1. Percentage and absolute numbers of participants with vaccinations against SARS-CoV-2 and comparator vaccinations who reported local or systemic reactions, each with their respective consequences. Multiple answers were possible. The consequence perceived as most serious is reported (from no consequence to medication intake, sick leave, ambulatory consultation, hospital outpatient consultation, and hospitalisation)
  2. BNT BNT162b2, MOD mRNA-1273, AZ ChAdOx1, JAN Ad26.COV2.S